At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,698 enrolled
Drug / intervention
Orforglipron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)
In Brief
A Phase 3 clinical trial evaluating Orforglipron and Semaglutide for Type 2 Diabetes. Completed, enrolled 1,698 participants across 131 sites in 6 countries.
Detailed Summary
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesArgentina, China, Japan, Mexico, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedSep 2023
Enrollment StartSep 2023
Primary CompletionAug 2025
TodayJul 2026
First PostedSep 21, 2023
Enrollment StartSep 22, 2023
Primary CompletionAug 22, 2025
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 2.8 years ago
Interventions
Orforgliprondrug
Administered orally
Semaglutidedrug
Administered orally